Wed, 08/04/2021 – 18:54
India represents the 5th largest pharmaceutical market in the world with a $41 billion size and growing at a rate of 16%. It is currently experiencing unforeseen business challenges by way of increased competition, changing consumer behavior, rising employee costs, and new disruptive, agile players. The Covid-19 pandemic has exacerbated this challenge further.
With changing customer behavior and digital disruption across sectors, can pharma brands continue to market products with the same go-to-market models as before?